The Pfizer vaccine is the first FDA approved COVID-19 vaccine and one of the most popular ones, but Moderna may soon take its place.
A study done on Moderna shows that twice as many antibodies are produced in comparison to Pfizer.
Dr. Bob Wachter, chair of the Department of Medicine at University of California, San Francisco, said that evidence has him leaning toward choosing Moderna for someone who has not already been vaccinated.
Dr. Peter Chin-Hong, an infectious disease expert at UCSF, said it’s hard to know what exactly causes it to perform better since they’re basically the same vaccine.
The biggest difference that may have an impact is that those receiving Moderna wait four weeks for their second dose, and those receiving Pfizer wait three weeks.
Chin-Hong stated that before basing a decision solely on this study, to remember that there are many antibodies produced that aren’t measured, like T cells.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].